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Purpose/Objective: GBM is most common primary brain tumor and 
represents an important challenge for clinicians. These neoplasms are 
resistant to radio-chemotherapy. This might be explained by the fact 
that interactions between tumor and microenvironment are involved 
in tumor radioresistance through angiogenesis, hypoxia and 
immunosuppression, or an intrinsic radioresistence of cancer stem 
cells. A molecular analysis in tumor samples or peripheral blood of 
basal activation of different signaling pathways potentially involved in 
radioresistance could be of clinical interest. Phosphatidyl-inositol 3-
kinase/protein kinase B (Akt) pathways serve to block apoptosis, 
keeping cells alive in very toxic environments such as chemotherapy 
and ionizing radiation. Polycomb group (PcG) proteins mediate gene 
silencing through histone post-translational modifications. PcG 
function is crucial for neural stem cell self-renewal. Recent evidence 
indicates that PcG genes are also required for cancer stem cell (CSC) 
propagation in neural tumors. In this study we evaluated the different 
genetic profile of Akt and EZH2 and clinical response to treatment in 
patient affected by GBM.  
Materials and Methods: Our plan is to analyze fifty patients with GBM 
treated with Radio-chemiotherapy (RT-CT) with temozolamede. Time 
to progression (TTP) after surgery or biopsy and overall survival (OS) 
will be used as clinical end-points to be correlated with 
polymorphisms of Akt and EZH2. DNA is extracted by proteinase K 
digestion. SNP genotyping was performed with the ABI PRISM 7900HT 
Sequence Detection System using primers and probes designed with 
Methyl Express software (v. 1.0). DNA samples (1-20 ng) from cancer 
tissue were amplified l multiplex Real-Time PCR. In addition, by 
quantifying themin a 25- fluorescent signals of the VIC and FAM 
probes, which specifically annealed to the two allelic sequences, the 
SDS software (v. 2.1) determined the allelic content of each sample. 
For the Quantitative Methyl Specific PCR, the Bisulfite treatment of 
DNA was performed using the Methyl SEQr Bisulfit system according to 
manufacturer’s protocol. Following bisulfite treatment, the converted 
DNA was amplified using primers designed for the altered sequences. 
Results: preliminary data is available for ninenteen patients for 
polymorphisms of Akt after a follow-up of three – thirty-six months. 
The Akt1*3 wild-type genotype was detected in 12/19 of samples and 
the heterozygous genotype was found in 7/19. We also evaluated 
Akt1*4 polymorphisms, and the only 2 patients that showed mutant 
genotype had the longest survival time. The same analysis will be 
performed in 42 peripheral blood in pts underwent to the same 
treatment for GBM, findings will be available for the ESTRO meeting in 
May.  
Conclusions: This study is currently ongoing, we actively accruing new 
cases and we are waiting for the data of peripheral blood. This 
preliminary analysis appears to indicate allelic discrimination of SNP’s 
is a senstive and reproducible method. The screening of cell line 
genotypes may add to the prognostic value of histopathology samples.  
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Purpose/Objective: Evaluation of 5-year treatment outcomes in high-
grade (grade III-IV) brain glioma patients administered conformal 
radio-(chemoradio)therapy. 
Materials and Methods: The study included 261 patients 22-74 years 
of age with Karnofsky perfomance scale of ≥ 50%. Fifty-four of them 
had pathological diagnoses of grade III anaplastic astrocytoma (AA), 17 
- grade III anaplastic oligoastrocytoma or grade III anaplastic 
oligodendroglioma (AO/AOD), and 190 - grade IV glioblastoma (GBM). 
In 2005 - 2010, 114 of them received a course of postoperative 
conformal radiotherapy at a single target dose of 1.8-2 Gy up to total 
target doses (TTD) of 54-60 Gy, and 147 patients in 2007 - 2011 
underwent a postoperative course of conformal chemoradiotherapy 
with temozolomide 75 mg/m2 an hour before radiation treatment 
during the first and the last 2 weeks of radiotherapy at the same 
doses. The patient survival was evaluated using the data of Belarusian 
Cancer Registry as of November 15, 2012 and calculated with Kaplan-
Meier method using the log-rank test and SPSS Statistics v.17 
software. 
Results: For the time being, 30 (55.6%) of 54 AA patients, 12 (70,6%) 
of 17 AO/AOD patients and 34 (17,9%) of 190 GBM patients are 
followed up. The median survival and 2-, 3- and 5-year survival rates 
for grade III gliomas are 33 months, 71.7±5.7%, 48.3±7.5% and 
39.1±8.5%; for grade IV GBM - 14 months, 22.6±3.2%, 11.2±2.7% and 
7.9±2.9% respectively (p<0.0001). The median survival of patients 
administered chemoradiotherapy for grade III glioma has not been 
attained yet, 3- and 5-year survival rates are 66.9±11.1%; the median 
survival of patients receiving radiotherapy is 29 months, and 3- and 5-
year survival rates are 36.8±8.9% and 27.6±8.8% respectively 
(p=0.034). For GBM treated with chemoradiotherapy, the median 
survival and 2-, 3- and 5-year survival rates are 16 months, 25.2±4.7%, 
11.1±3.9% and 7.4±4.0%; with radiotherapy - 12 months, 18.3±4.3%, 
9.8±3.3% and 8.4±3.1% respectively (p=0.035). The median survival for 
AO/AOD was higher then for AA and was 46 months and 29 months 
respectively (p=0.069). 
Conclusions: Postoperative conformal radio-(chemoradio) therapy at a 
TTD of 54-60 Gy provides 2-, 3- and 5-year survival rates of 71.7±5.7%, 
48.3±7.5%, 39.1±8.5% and 22.6±3.2%, 11.2±2.7%, 7.9±2.9% for grade III 
anaplastic glioma patients and grade IV GBM patients respectively, 
with median survival of 33 and 14 months respectively (p<0.0001). 
Postoperative conformal chemoradiotherapy improves treatment 
outcomes compared with radiotherapy for both anaplastic gliomas 
(p=0.034) and GBM (p=0.035).  
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Purpose/Objective: To review the safety and activity of radiotherapy 
with concurrent bevacizumab in recurrent malignant gliomas. Reasons 
to combine bevacizumab and RT include the ability of antiangionetic 
agents to senzitize tumor endothelium to RT by depletion of VEGF and 
reduction of its pro-survival signaling. Our retrospective analysis 
provides additional data out of a very limited number of studies about 
safety and feasibility of conventionel 3D-conformal re-irradiation in 
combination with bevacizumab as a salvage therapy for relapsed 
gliomas. 
Materials and Methods: Patients with recurrence of malignant gliomas 
who failed after standard treatment odf surgery, post operative 
radiotherapy ± Temozolomide received bevacizumab (10 mg/kg i.v.) 
every two weeks until tumor progression and hypofractionated (16 x 
2.66 Gy). The intervall between the two radiotherapy treatments was 
at least 4 months in our patients. The median physical doses of the 
first and second radiation course were 40-60 Gy and 39-60 Gy, 
respectively. The median cumulative biological equivalent doses (BED) 
were 215 Gy (α/β = 2 gy) and 100 Gy (α/β = 10 Gy): Median RT-volume 
was 143 cm³ and median cumulative RT-dose was 95 Gy.  
Results: 13 consecutive patients with reccurrent malignant gliomas (6 
GBM, 3 AAC, 3 LGG, 1 not applicable) received 2 cycles of 
bevacizumab prior to re-irradiation and underwent a repeat cranial 
MRI-scan for RT-planing. Patinets who respond or had SD proceed to 
radiation therapy in a 3D-conformal manner to 16 x 2.66 Gy: PTV 
inclosed the contrast-enhancing GTV, the surroundig oedema plus a 
additional margins of 2.5 cm. Critical structures like the optic chiasm 
were excluded and the dose to the re-irradiated target volume was 
restricted to a cumulative dose of 110 Gy. No Grade 3-4 acute toxicity 
developed, haematologic and non haematologic toxicities were 
transient. Until now 1 necrosis is seen in this cohort and all patients 
responded to therapy. The median PFS after re-irradiation is 4.9 
months, the median OS after re-irradiation is 8.2 months. 
Conclusions: 3D-conformal re-irradiation ± bevacizumab is save with a 
good quality of life for progressive HGG patients. The large re-
irradiation volumes were well tolerated with a low rate of one 
confirmed radiation necrosis in 13 patients. Pretreatment with 
radiochemotherapy (temozolomide) does not increase neurotoxicity. 
The PFS is comparable to more complex and less abundant high 
precission radiation techniques.  
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